Journals / Koşuyolu Kalp Dergisi / 2017 / Cilt: 20 - Sayı: 1

Biyoprotez Aort Kapak Replasmanı Sonrası Görülebilen Trombositopeni ve İlişkili Komplikasyonların Değerlendirilmesi

Evaluation of Thrombocytopaenia-Related Complications After Bioprosthetic Aortic Valve Implantation

Pages
47–52
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, 30-day mortality occurred in 3 (7.7%) patients, and the difference between the groups wasnot statistically significant.Conclusion: Postoperative TCP may be associated with a substantial threat for the postoperative status ofpatients undergoing bioprosthetic valve replacement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: We aimed to determine whether thrombocytopaenia (TCP) is associated with postoperativecomplications in patients undergoing bioprosthetic aortic valve replacement.Patients and Methods: Clinical records of 39 consecutive patients undergoing bioprosthetic aortic valvereplacement for aortic stenosis were reviewed.
📊
Key Findings & Data:Patients were divided into 2 groups based on whether they hadTCP or not within 7 days after the operation [TCP (+), 9 patients and TCP (-), 30 patients].
💡
Conclusion & Impact:Overall, 30-day mortality occurred in 3 (7.7%) patients, and the difference between the groups wasnot statistically significant.Conclusion: Postoperative TCP may be associated with a substantial threat for the postoperative status ofpatients undergoing bioprosthetic valve replacement.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: We aimed to determine whether thrombocytopaenia (TCP) is associated with postoperativecomplications in patients undergoing bioprosthetic aortic valve replacement.Patients and Methods: Clinical records of 39 consecutive patients undergoing bioprosthetic aortic valvereplacement for aortic stenosis were reviewed. Patients were divided into 2 groups based on whether they hadTCP or not within 7 days after the operation [TCP (+), 9 patients and TCP (-), 30 patients]. TCP was definedas a platelet count less than 50 × 109/L.Results: Both the groups were similar with regard to baseline clinical characteristics and operative variables.Stentless bioprosthesis was used in 16 patients (41.02%). The use of Sorin Pericarbon Freedom wassignificantly more common in the TCP (+) group. Postoperative complications such as the removal time ofthe drainage tube, intensive care unit (ICU) stay and acute renal failure were significantly higher in the TCP(+) group. Overall, 30-day mortality occurred in 3 (7.7%) patients, and the difference between the groups wasnot statistically significant.Conclusion: Postoperative TCP may be associated with a substantial threat for the postoperative status ofpatients undergoing bioprosthetic valve replacement. The issue is still subject to further research until theexact mechanism underlying its occurrence is elucidated.

Özet

Giriş: Biyoprotez aort kapak replasmanı yapılan hastalarda görülebilen trombositopeninin (TCP) postoperatifkomplikasyonlar ile ilişkili olup olmadığını belirlemeyi amaçladık.Hastalar ve Yöntem: Aort darlığı nedeniyle biyoprotez aort kapak replasmanı yapılan 39 ardışık hastanın klinikkayıtları incelendi. Hastalar operasyondan sonraki 7 güne kadar trombositopeni görülen ve görülmeyenlerolarak iki gruba ayrıldı. (TCP+; 9 hasta ve TCP-; 30 hasta) Trombositopeni, 50 x 109/L'den az trombosit sayısıolarak tanımlandı.Bulgular: İki grup bazal klinik özellikleri ve operasyonel değişkenler açısından benzerdi. Stentsiz biyoprotezkapak 16 hastada kullanıldı (41.02%). Sorin Pericarbon Freedom kullanımı TCP (+) grubunda anlamlı olarakdaha yaygındı. Drenaj tüplerinin çekilme süresi, yoğun bakım ünitesi (YBÜ)'nde kalış süresi ve akut böbrek yetmezliğigibi postoperatif komplikasyonlar, TCP (+) grupta anlamlı olarak yüksek bulundu. Otuz günlük mortalite3 (%7.7) idi ve mortalite açısından iki grup arasındaki fark istatistiksel olarak anlamlı değildi.Sonuç: Biyoprotez aort kapak replasmanı sonrası görülebilen trombositopeni tablosu, hastalar için önemlibir tehdit ile ilişkili olabilmektedir. Bu fenomenin oluş mekanizması tam olarak aydınlatılamamış olmaklaberaber yüksek sayılı araştırmalara tabi tutulması gerekmektedir.

🔖

Cite This Article

ALTAŞ, Ö., KIRALİ, K., SARIKAYA, S., ÇEKMECELİOĞLU, D., DEDEMOĞLU, M., ÖZEN, Y., AKSOY, E. (2022). Biyoprotez Aort Kapak Replasmanı Sonrası Görülebilen Trombositopeni ve İlişkili Komplikasyonların Değerlendirilmesi. Koşuyolu Kalp Dergisi, Cilt: 20 - Sayı: 1, 47–52. https://ajindex.com/articles/576058

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kuehnel RU, Pohl A, Puchner R, Wendt MO, Hartrumpf M, Pohl M, et al. Opening and closure characteristics of different types of stented biological valves. Thorac Cardiovasc Surg 2006;54:85-90
  2. Gulbins H, Reichenspurner H. Which patients benefit from stentless aortic valve replacement? Ann Thorac Surg 2009;88:2061-8
  3. Nyawo B, Graham R, Hunter S. Aortic valve replacement with the Sorin Pericarbon Freedom stentless valve: five-year follow up. J Heart Valve Dis 2007;16:42-8
  4. Kunadian B, Vijayalakshmi K, Thornley AR, de Belder MA, Hunter S, Kendall S, et al. Meta-analysis of valve hemodynamics and left ventricular mass regression for stentless versus stented aortic valves. Ann Thorac Surg 2007;84:73-8
  5. Perez de Arenaza D, Lees B, Flather M, Nugara F, Husebye T, Jasinski M, et al; ASSERT (Aortic Stentless versus Stented valve assessed by Echocardiography Randomized Trial) Investigators. Randomized comparison of stentless versus stented valves for aortic stenosis: effects on left ventricular mass. Circulation 2005;112:2696-702
  6. Doss M, Martens S, Wood JP, Aybek T, Kleine P, Wimmer Greinecker G, et al. Performance of stentless versus stented aortic valve bioprosthesis in the elderly patient: a prospective randomized trial. Eur J Cardiothorac Surg 2003;23:299-304
  7. Westaby S. Implant technique for the Sorin stentless pericardial valve. Oper Tech Thorac Cardiovasc Surg 2001;6:101-5
  8. Aymard T, Eckstein F, Englberger L, Stalder M, Kadner, A, Carrel, T. The Sorin Freedom SOLO stentless aortic valve: technique of implantation and operative results in 109 patients. J Thorac Cardiovasc Surg 2010;139:775-7
  9. Yerebakan C, Kaminski A, Westphal B, Kundt G, Ugurlucan M, Steinhoff G, et al. Thrombocytopenia after aortic valve replacement with the Freedom Solo stentless bioprosthesis. Interact Cardiovasc Thorac Surg 2008;7:616-20
  10. Piccardo A, Rusinaru D, Petitprez B, Marticho P, Vaida I, Tribouilloy C, et al. Thrombocytopenia after aortic valve replacement with freedom solo bioprosthesis: a propensity study. Ann Thorac Surg 2010;89:1425-30
  11. Kolseth SM, Nordhaug D, Stenseth R, Wahba A. Initial experience with the Freedom Solo® stentless aortic valve in a low volume centre. Scand Cardiovasc J 2010;44:301-6
  12. Reents W, Babin-Ebell J, Zacher M, Diegeler A. Thrombocytopenia after aortic valve replacement with the Sorin Freedom Solo prosthesis. J Heart Valve Dis 2011;20:313-8
  13. Gersak B, Gartner U, Antonic M. Thrombocytopenia following implantatio